Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

被引：4
|
作者：
Kansagra, Ankit
Lin, Yi
Berdeja, Jesus G.
Shah, Nina
Oriol, Albert
Yakoub-Agha, Ibrahim
Einsele, Hermann
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Rowe, Everton
Wang, Julie
Agarwal, Amit
Campbell, Timothy B.
Lonial, Sagar
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134383
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY
    Jesus, San-Miguel
    Noopur, Raje S.
    David, Siegel
    Sundar, Jagannath
    Sagar, Lonial
    Nikhil, Munshi C.
    Philippe, Moreau
    Hartmut, Goldschmidt
    Michele, Cavo
    Anna, Truppel-Hartmann
    Everton, Rowe
    Huang Liping
    Amit, Agarwal
    Julie, Wang
    Timothy, Campbell B.
    Donna, Reece E.
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 77
  • [22] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A CAR T THERAPY TARGETING BCMA, IN PATIENTS WITH MULTIPLE RECLAIMER/REFRACTORY MYELOMA (MMRR): UPDATE FROM THE KarMMa STUDY
    Albert, Oriol
    Jesus, San-Miguel
    Ankit, Kansagra
    Deepu, Madduri
    Nina, Shah
    Philippe, Moreau
    Ibrahim, Yakoub-Agha
    Michel, Delforge
    Michele, Cavo
    Hermann, Einsele
    Hartmut, Goldschmidt
    Katja, Weisel
    Alessandro, Rambaldi
    Donna, Reece
    Paula, Rodriguez-Otero
    Fabio, Petrocca
    Jamie, Connarn N.
    Payal, Patel
    Huang Liping
    Timothy, Campbell B.
    Kristen, Hege
    Nikhil, Munshi C.
    HAEMATOLOGICA, 2021, 106 (10) : 76 - 77
  • [23] Healthcare resource utilization and economic burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel, bb2121) in KarMMa.
    Hari, Parameswaran
    Nguyen, Andy
    Pelletier, Corey
    McGarvey, November
    Gitlin, Matthew
    Parikh, Kejal
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [24] ESTIMATION OF POST-INFUSION COSTS OF CARE FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN THE KARMMA CLINICAL TRIAL
    Hari, P.
    Nguyen, A.
    Pelletier, C.
    Hege, K.
    McGarvey, N.
    Gitlin, M.
    Parikh, K.
    VALUE IN HEALTH, 2021, 24 : S29 - S30
  • [25] Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
    Thompson, Ethan G.
    Jiang, Yue
    Campbell, Timothy B.
    Fuller, Jaymes
    Kaiser, Shari
    Mashadi-Hossein, Afshin
    Rytlewski, Julie
    Martin, Nathan
    Finney, Olivia
    Kleinsteuber, Katja
    Alonzo, Eric
    Pandya, Chetanya
    Agarwal, Amit
    Hege, Kristen
    Raje, Noopur S.
    Munshi, Nikhil C.
    Hause, Ronald J.
    BLOOD, 2019, 134
  • [26] Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial
    McGarvey, November
    Ung, Brian
    Carattini, Thomas
    Campbell, Timothy
    Lee, Abraham
    Patwardhan, Pallavi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S181
  • [27] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Einsele, Hermann
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    Munshi, Nikhil C.
    Oriol, Albert
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
  • [28] Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Connarn, Jamie
    Patel, Payal
    Huang, Liping
    Campbell, Timothy Brandon
    Hege, Kristen
    San Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
    Delforge, Michel
    Baz, Rachid C.
    Cavo, Michele
    Callander, Natalie S.
    Ghobadi, Armin
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Massaro, Monica
    Ding, Li
    Patel, Payal
    Pittari, Gianfranco
    Novick, Steven
    Giralt, Sergio A.
    Berdeja, Jesus G.
    BLOOD, 2020, 136
  • [30] Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial
    Ayers, Dieter
    Cope, Shannon
    Dhanda, Devender S.
    Towle, Kevin
    Mojebi, Ali
    Delforge, Michel
    Rodriguez-Otero, Paula
    Trudel, Suzanne
    Weisel, Katja
    Zamagni, Elena
    Hari, Parameswaran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S139 - S140
12345